Expanded GLP-1 Medication Access Through Formulary Updates

CVS Caremark’s latest formulary changes are poised to strengthen GLP-1 Medication Access for commercial plan members by restoring coverage for select weight-management therapies.

Effective October 1, 2026, Zepbound returns as a preferred option on template formularies for sponsors that elect coverage, while Foundayo loses its new-to-market block on June 1, 2026. These moves expand GLP-1 Medication Access without removing plan sponsors’ ability to tailor benefits.

Negotiated Savings Drive Affordability

Direct manufacturer negotiations delivered double-digit year-over-year net-cost reductions, allowing the reintroduction of Zepbound and addition of an oral GLP-1 agent. The resulting flexibility helps sponsors balance member needs with overall plan sustainability.

Ad

CVS Caremark negotiates acquisition prices and placement decisions on behalf of employers and health plans, using independent Pharmacy & Therapeutics review to weigh clinical value against cost.

Path to Sustainable Reimbursement

Targeted pricing agreements reduce pressure for coverage limits and support more durable market access for high-demand therapies.